Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia.

Autor: Horn B; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Wahlstrom JT; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Melton A; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Liou A; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Ouachee-Chardin M; Immuno-Hematology Unit, Robert Debre Hospital, Paris, France., Sunkersett G; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Willert J; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Hwang J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Expose-Spencer J; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Cowan MC; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Facchino J; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California., Dvorak CC; Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2017 Aug; Vol. 64 (8). Date of Electronic Publication: 2017 Feb 16.
DOI: 10.1002/pbc.26464
Abstrakt: This retrospective analysis comprises 10-year experience with early posttransplant mixed chimerism-based preemptive intervention. Out of 104 patients, 51 received preemptive immunotherapy. Their outcomes were similar to patients achieving full donor chimerism spontaneously. Among patients receiving intervention, 5-year event-free survival was identical in patients with and without pretransplant residual disease, respectively (68% [95% confidence interval (CI) 38-98%] vs. 69% [95% CI 54-85%] log-rank = 0.4). In patients who received preemptive immunotherapy, chimerism status and residual disease prior to transplant were no longer predictors of poor outcome; however, 41% of the patients with residual disease prior to transplant relapsed early and did not benefit from this strategy.
(© 2017 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: